These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32138869)

  • 1. Antiretroviral Therapies for Human Immunodeficiency Virus and Liver Disease: Challenges and opportunities.
    Abarca JC; Huerta L; Fierro NA
    Ann Hepatol; 2020; 19(2):121-122. PubMed ID: 32138869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV.
    Rockstroh JK
    Curr HIV/AIDS Rep; 2017 Apr; 14(2):47-53. PubMed ID: 28284005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver disease in the HIV-infected individual.
    Price JC; Thio CL
    Clin Gastroenterol Hepatol; 2010 Dec; 8(12):1002-12. PubMed ID: 20851211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver Disease in Human Immunodeficiency Virus Infection.
    Oikonomou KG; Tsai E; Sarpel D; Dieterich DT
    Clin Liver Dis; 2019 May; 23(2):309-329. PubMed ID: 30947879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-related liver disease: ARV drugs, coinfection, and other risk factors.
    Puoti M; Nasta P; Gatti F; Matti A; Prestini K; Biasi L; Carosi G
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(1):30-42. PubMed ID: 19211929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hepatic complications in HIV-infected persons.
    Sulkowski MS
    J Infect Dis; 2008 May; 197 Suppl 3():S279-93. PubMed ID: 18447614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sociodemographic and clinical factors associated with the preference between NNRTIs and PIs for the initial treatment of HIV infection: Perfil-es study.
    Viciana P; Ocampo A; Hevia H; Palazuelos M; Ledesma F
    AIDS Care; 2016 Oct; 28(10):1321-6. PubMed ID: 27140483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Causes and outcomes of hepatic fibrosis in persons living with HIV.
    Yen DW; Sherman KE
    Curr Opin HIV AIDS; 2022 Nov; 17(6):359-367. PubMed ID: 36165079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir.
    Palacios R; Vergara S; Rivero A; Aguilar I; Macías J; Camacho A; Lozano F; García-Lázaro M; Pineda JA; Torre-Cisneros J; Márquez M; Santos J
    HIV Clin Trials; 2006; 7(6):319-23. PubMed ID: 17197379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic liver disease in the human immunodeficiency virus patient.
    Acharya C; Dharel N; Sterling RK
    Clin Liver Dis; 2015 Feb; 19(1):1-22. PubMed ID: 25454294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Liver Pathology.
    Sonderup MW; Wainwright HC
    Gastroenterol Clin North Am; 2017 Jun; 46(2):327-343. PubMed ID: 28506368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver as a target of human immunodeficiency virus infection.
    Ganesan M; Poluektova LY; Kharbanda KK; Osna NA
    World J Gastroenterol; 2018 Nov; 24(42):4728-4737. PubMed ID: 30479460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling hepatotoxicity and antiretroviral therapeutic effect in HIV/HBV coinfection.
    Nampala H; Luboobi LS; Mugisha JYT; Obua C; Jablonska-Sabuka M
    Math Biosci; 2018 Aug; 302():67-79. PubMed ID: 29800563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy.
    Ingiliz P; Valantin MA; Duvivier C; Medja F; Dominguez S; Charlotte F; Tubiana R; Poynard T; Katlama C; Lombès A; Benhamou Y
    Hepatology; 2009 Feb; 49(2):436-42. PubMed ID: 19085967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of antiretroviral therapy on liver disease.
    Kovari H; Weber R
    Curr Opin HIV AIDS; 2011 Jul; 6(4):272-7. PubMed ID: 21508839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection.
    Bonacini M
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S104-8. PubMed ID: 14986282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms.
    Pol S; Lebray P; Vallet-Pichard A
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S65-72. PubMed ID: 14986277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C and human immunodeficiency virus coinfections.
    Dodig M; Tavill AS
    J Clin Gastroenterol; 2001; 33(5):367-74. PubMed ID: 11606851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NNRTI hepatotoxicity: efavirenz versus nevirapine.
    Pulido F; Torralba M
    J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.